Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.

Oncotarget - 6 Sept 2016

Du Yue, Shang Bo-Yang, Sheng Wei-Jin, Zhang Sheng-Hua, Li Yi, Miao Qing-Fang, Zhen Yong-Su

Abstract excerpt

K-Ras mutant pancreatic cancer cells display intensive macropinocytosis, indicating that this process may be exploited in the design of anticancer targeted therapies. In this study, we constructed a macropinocytosis-oriented recombinantly tailored defensin (DF-HSA) which consists of human β-defensin-2 (DF) and human serum albumin (HSA). The macropinocytosis intensity and cytotoxicity of DF-HSA were investigated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to beta-Defensins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Membrane Potential, Mitochondrial

Share to Mice, Nude

Share to Neoplasm Transplantation

Share to Pancreatic Neoplasms

Share to Pinocytosis

Share to Reactive Oxygen Species

Source

Open in PubMed Open full text

Identifiers

PMID: 27517152
DOI: 10.18632/oncotarget.11170
PMCID: PMC5295440

Genes

MIA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.PMID 27517152Read ↗

Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer.Semantic proximity Read ↗

The Dual Role of Macropinocytosis in Cancers: Promoting Growth and Inducing Methuosis to Participate in Anticancer Therapies as TargetsSemantic proximity Read ↗

Novel selective inhibitors of macropinocytosis-dependent growth in pancreatic ductal carcinoma.Semantic proximity Read ↗

Targeted Nanoencapsulation of Tunicamycin Reduces Toxicity While Improving its Therapeutic Effectiveness in Pancreatic Cancer CellsSemantic proximity Read ↗

Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.Semantic proximity Read ↗

Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer.Semantic proximity Read ↗

Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.Semantic proximity Read ↗

Survival strategies of cancer cells: the role of macropinocytosis in nutrient acquisition, metabolic reprogramming, and therapeutic targetingSemantic proximity Read ↗

Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosisSemantic proximity Read ↗

An albumin‑binding domain and targeting peptide‑based recombinant protein and its enediyne‑integrated analogue exhibit directional delivery and potent inhibitory activity on pancreatic cancer with K‑ras mutation.Semantic proximity Read ↗

Gold Nanoparticles Inhibit Macropinocytosis by Decreasing KRAS Activation.Semantic proximity Read ↗

KRAS mutation-driven enhanced macropinocytosis: using albumin as a trojan horse for delivering nanomedicine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.